the glocalized network in theragenomic and personalized medicine and the genetics of individual patients safety of drugs
May 06, 2018 – In April 2016 the American Food and Drug Administration (FDA) took regulatory action by mandating label changes with new warnings about an increased risk of heart failure for new diabetes medicines in the dipeptidyl peptidase-4 (DPP-4) …
Heart attacks and stroke: The risk of DPP-4 anti-diabetes drugs Read more »
April o5, 2016 – There have been indications that a heightened risk of heart failure may be associated with diabetes medications containing the pharmacologically active ingredients saxagliptin or alogliptin. In the US, this includes the FDA-approved drugs Saxagliptin (Onglyza), Saxagliptin/Metformin …
October 02, 2015 – Recently, the American Food and Drug Administration (FDA) approved Sacubitril/Valsartan (Entresto) for the treatment of heart failure. Similarly, a few days ago, the European Medicines Agency (EMA) recommended granting a marketing authorisation for Sacubitril/Valsartan (Entresto) for the treatment of adults with symptomatic chronic heart failure …